Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 1 2

Status

Terminated 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2Other hematologic neoplasm 1

Conditions

Lymphoma, Large B-Cell, Diffuse 6Lymphoma, Non-Hodgkin 2Lymphoma, Mantle-Cell 2Lymphoma, Follicular 2Lymphoma, B-Cell 2Lymphoma 2Leukemia, Lymphocytic, Chronic, B-Cell 2Burkitt Lymphoma 2Waldenstrom Macroglobulinemia 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1

Interventions

Rituximab 43Cyclophosphamide 41fludarabine phosphate 24Filgrastim 19fludarabine 16Lenalidomide 15Bendamustine Hydrochloride 15Peripheral Blood Stem Cell Transplantation 14Bortezomib 13Etoposide 11venetoclax 10ibrutinib 10Radiotherapy 10Biopsy 10aldesleukin 9Vincristine 9Prednisone 9Magnetic Resonance Spectroscopy 9Vorinostat 8Specimen Handling 8Cytarabine 8Cyclosporine 8pembrolizumab 7obinutuzumab 7Paclitaxel 7Gemcitabine 7Flow Cytometry 7tanespimycin 6Tacrolimus 6Methylprednisolone 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Lymphoma, Follicular × loncastuximab tesirine × Clear all
NCT03685344 2021-10-26

Safety and Antitumor Activity Study of Loncastuximab Tesirine and Durvalumab in Diffuse Large B-Cell, Mantle Cell, or Follicular Lymphoma

ADC Therapeutics S.A.

Phase 1 Terminated
13 enrolled 15 charts
Lymphoid

Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell

NCT02669017 2021-05-19

Study of ADCT-402 in Patients With Relapsed or Refractory B-cell Lineage Non Hodgkin Lymphoma (B-NHL)

ADC Therapeutics S.A.

Phase 1 Completed
183 enrolled 38 charts
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡